



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd
Addysgu Powys
Powys Teaching
Health Board

Information Governance Team
Monnow Ward
Bronllys Hospital
Bronllys
Brecon
Powys LD3 0LY
Email: Powys.FOI@wales.nhs.uk
Tel: 01686 252170 / 01874 442071

Our ref: IG/FOI/FOI.199.26

11 June 2026

Sent via email to: [REDACTED]

Dear [REDACTED]

Request under the Freedom of Information Act 2000

I write further to your request for information which was received on 15 May 2026, to confirm, in accordance with S.1(1)(a) of the Freedom of Information Act 2000, that Powys Teaching Health Board (PTHB) partly holds the information that you require. For ease of reference your request is set out below and the Health Board's response follows each question individually.

Your Freedom of Information (FOI) Request and Powys Response (Bold):

I am analysing the usage of intra-vitreous injections or implants by the NHS. I would greatly appreciate if you could answer the following questions.

Please note for both questions, if a patient has received multiple injection/implants in the time period specified of January to April 2026, please count the total number of injections/implants that the Trust has administered. I.e. if a patient has received two injections/implants please count that as two.

Q1. How many of the following intra-vitreous injections/implants has your trust administered in the four-month period from January to April 2026:

- Aflibercept – Eylea - **(2mg and 8mg) 62**
- Aflibercept – Biosimilar - **89**
- Bevacizumab - **0**
- Brolucizumab - **0**
- Dexamethasone - **0**
- Faricimab - **160**
- Fluocinolone acetonide - **0**
- Ranibizumab - including all Biosimilars - **165**

Pencadlys
Tŷ Glasbury, Ysbyty Bronllys,
Aberhonddu, Powys LD3 0LU
Ffôn: 01874 711661

Headquarters
Glasbury House, Bronllys Hospital
Brecon, Powys LD3 0LU
Tel: 01874 711661

Q2. Please provide the number of injections/implants by eye condition for the four-month period from January to April 2026:

- Aflibercept - Eylea
- Aflibercept - Biosimilar
- Bevacizumab
- Dexamethasone
- Faricimab
- Fluocinolone acetonide
- Ranibizumab - including all Biosimilars

Treatment	Eye Condition			
	Wet Age-Related Macular Degeneration	Diabetic Macular Oedema (DMO)	Retinal Vein Occlusion (RVO)	Non-infectious Uveitis (NIU)
Aflibercept - Eylea				n/a
Aflibercept - Biosimilar				n/a
Bevacizumab				n/a
Dexamethasone				
Faricimab				n/a
Fluocinolone acetonide				
Ranibizumab - including all Biosimilars				n/a

Please note that the data is not centrally collated in the format requested in Table 1 and, therefore, we are unable to provide it in that format. However, we are able to provide the information in the alternative format set out in Table 2 below.

Diagnosis	Aflibercept (Eylea)	Aflibercept (8mg)	Faricimab (Vabysmo)	Mynzept	Ranibizumab (Rimmyrah)
AMD - not specified	20	9	99	44	119
Classic CNV	3	1	7	3	3
CNV 2° to angioid streaks	1	0	0	1	0
CNV other	0	2	10	2	2
Diabetic macular edema (meeting NICE guidance)	4	2	7	5	13
Macular oedema 2° to BRVO	11	1	3	16	13
Macular oedema 2° to CRVO	5	0	10	7	6

Minimally classic CNV	0	0	2	3	3
Myopic CNV	1	0	1	1	4
Occult CNV	3	5	15	6	2
Peripapillary CNV	1	0	0	1	5
Not Recorded	0	0	4	1	0
Predominantly classic CNV	0	0	2	0	0

If you are dissatisfied with the handling or response to your request, you have the right to ask for an internal review. Should you wish an internal review, please quote the reference number and send your correspondence to the above address.

If you are not content with the outcome of the internal review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at:

Address: Information Commissioner's Office (Wales), 2nd Floor, Churchill House, Churchill Way, Cardiff, CF10 2HH.

Telephone: 0330 414 6421

Complaints Portal: www.ico.org.uk/foicomplaints

Web site: <https://ico.org.uk/>

Re-use of Public Sector Information

All information supplied by the Health Board in answering a request for information (RFI) under the Freedom of Information Act 2000 will be subject to the terms of the Re-use of Public Sector Information Regulations 2015.

Under the terms of the Regulations, the Health Board will licence the re-use of any or all information supplied if being used in a form and for the purpose other than which it was originally supplied. This license for re-use will be in line with the requirements of the Regulations and the licensing terms and fees as laid down by the Office of Public Sector Information (OPSI). Most licenses will be free; however, the Health Board reserves the right, in certain circumstances to charge a fee for the re-use of some information which it deems to be of commercial value.

Further information including a sample license terms and fees can be found at [Open Government Licence](#).

Yours sincerely



Kate Wright
Executive Medical Director

Rydym yn croesawu derbyn gohebiaeth yng Nghymraeg. Byddwn yn ateb y fath ohebiaeth yng Nghymraeg ac ni fydd hyn yn arwain at oedi.

We welcome receiving correspondence in Welsh. We will reply to such correspondence in Welsh and this will not lead to a delay.